Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers.

Bibliographic Details
Main Authors:	Moorthy, V, McConkey, S, Roberts, M, Gothard, P, Arulanantham, N, Degano, P, Schneider, J, Hannan, C, Roy, M, Gilbert, S, Peto, T, Hill, A
Format:	Journal article
Language:	English
Published:	2003

Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers
by: Moorthy, V, et al.
Published: (2003)

Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers.
by: Webster, D, et al.
Published: (2006)

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
by: McConkey, S, et al.
Published: (2003)

Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models.
by: Dégano, P, et al.
Published: (1999)

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.
by: Moorthy, V, et al.
Published: (2003)

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara.
by: Webster, D, et al.
Published: (2005)

Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations.
by: Gilbert, S, et al.
Published: (1999)

Therapeutic vaccination against hepatitis B virus using heterolgous prime boost strategy with DNA and modified vaccinia virus ankara vectors
by: McConkey, S, et al.
Published: (2003)

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara.
by: Schneider, J, et al.
Published: (1998)

Clinical development of Modified Vaccinia virus Ankara vaccines
by: Gilbert, S
Published: (2013)

Clinical development of Modified Vaccinia virus Ankara vaccines.
by: Gilbert, S
Published: (2013)

A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees.
by: Schneider, J, et al.
Published: (2001)

Deletion of fifteen open reading frames from modified vaccinia virus Ankara fails to improve immunogenicity
by: Alharbi, N, et al.
Published: (2015)

A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.
by: Dunachie, S, et al.
Published: (2006)

Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses.
by: Reyes-Sandoval, A, et al.
Published: (2010)

DNA-based vaccines for malaria: a heterologous prime-boost immunisation strategy.
by: Hill, A, et al.
Published: (2000)

Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction.
by: Behboudi, S, et al.
Published: (2004)

Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity.
by: Naif Khalaf Alharbi, et al.
Published: (2015-01-01)

Erratum: Prime-boost immunization with adenoviral and modified vaccinia virus ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses
by: Reyes-Sandoval, A, et al.
Published: (2011)

Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area.
by: Bejon, P, et al.
Published: (2006)

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).
by: Cottingham, M, et al.
Published: (2008)

Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein.
by: Walther, M, et al.
Published: (2006)

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).
by: Matthew G Cottingham, et al.
Published: (2008-02-01)

Increased detection of proliferating, polyfunctional, HIV-1-specific T cells in DNA-modified vaccinia virus Ankara-vaccinated human volunteers by cultured IFN-gamma ELISPOT assay.
by: Winstone, N, et al.
Published: (2009)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
by: Olga Vladimirovna Orlova, et al.
Published: (2022-09-01)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
by: Volker Sandig, et al.
Published: (2013-11-01)

Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8(+) T-Cell Responses, (vol 78, pg 152, 2010)
by: Reyes-Sandoval, A, et al.
Published: (2011)

Correction: Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA).
by: Matthew G. Cottingham, et al.
Published: (2011-01-01)

Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria.
by: Keating, S, et al.
Published: (2005)

Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice.
by: Hanke, T, et al.
Published: (1998)

Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya.
by: Bejon, P, et al.
Published: (2006)

Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya
by: Bejon, P, et al.
Published: (2006)

Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara.
by: Smith, C, et al.
Published: (2005)

Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.
by: Goonetilleke, N, et al.
Published: (2003)

Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
by: Kaïdre Bendjama, et al.
Published: (2017-09-01)

Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?
by: Malachy I. Okeke, et al.
Published: (2017-10-01)

Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis.
by: Gilbert, S, et al.
Published: (2006)

Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis.
by: Mcshane, H, et al.
Published: (2001)

Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP
by: Rampling, T, et al.
Published: (2016)

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.
by: McShane, H, et al.
Published: (2004)

Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers.

Similar Items

Similar Items